Defunct Company
Total Trials
15
As Lead Sponsor
14
As Collaborator
1
Total Enrollment
3,597
NCT00073853
Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries
Phase: Phase 2
Role: Lead Sponsor
Start: Sep 30, 2003
Completion: Not specified
NCT02369965
Test Albuvirtide in Experienced Patients
Phase: Phase 3
Start: Feb 19, 2014
Completion: Apr 2, 2018
NCT02436824
A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain
Start: Apr 30, 2015
Completion: Aug 31, 2015
NCT03719664
Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects
Start: Dec 17, 2018
Completion: Dec 31, 2022
NCT03997734
Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects
Phase: Phase 1
Start: Jun 24, 2019
Completion: Nov 11, 2019
NCT04766931
The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection
Start: Mar 17, 2021
Completion: Aug 12, 2022
NCT04819347
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
Start: May 1, 2021
Completion: Dec 1, 2022
NCT04560569
Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
Start: Nov 30, 2021
NCT05197179
A Bridging Study of FB2001 in Healthy Subjects
Start: Dec 29, 2021
Completion: Jun 2, 2022
NCT05206019
Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection
Start: Feb 16, 2022
Completion: May 2, 2022
NCT05415241
Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close Contacts
Phase: Phase 1/2
Role: Collaborator
Start: Jun 9, 2022
NCT05445934
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)
Phase: Phase 2/3
Start: Sep 14, 2022
Completion: Dec 31, 2023
NCT05583812
A Study of FB2001 for Inhalation in Healthy Chinese Adults
Start: Oct 21, 2022
Completion: Dec 30, 2022
NCT05675072
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
Start: Jan 4, 2023
NCT06510413
An Bioequivalence Study of Loxoprofen Sodium Patches in Healthy Volunteers
Start: Jul 31, 2024
Completion: Aug 31, 2024